| Project/Area Number |
17K10654
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Showa University (2020-2022)
Nigata University of Phermacy and Applied Life Sciences (2017-2019) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
梅本 岳宏 昭和大学, 医学部, 講師 (00384537)
|
|---|
| Project Period (FY) |
2017-04-01 – 2023-03-31
|
| Project Status |
Completed (Fiscal Year 2022)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
|
|---|
| Keywords | 遺伝子多型 / 化学療法 / 末梢神経毒性 / 個別化医療 / 副反応 / 神経毒性 / 安全性 / 抗EGFR抗体 / PNQ / オキサリプラチン / 大腸癌 / KRAS / 遺伝子変異 / BRAF / RAS / PIK3CA / ダイレクトシークエンス / 癌 / 遺伝子 / 外科 / 薬学 / 臨床 |
|---|
| Outline of Final Research Achievements |
We analyzed polymorphisms of the RAF/RAS gene in patients with colorectal cancer treated with chemotherapy FOLFOX or FOLFIRI in combination with an anti-EGFR antibody drug for the treatment of patients with unresectable/advanced recurrent colorectal cancer with wild-type RAS gene. Subjects were patients with stage III-IV colorectal cancer (mCRC) who underwent FOLFOX ± CET combination therapy. Three specimens of blood, non-cancer site, and cancer site were provided from the same patient for the samples used for gene polymorphism analysis. Genomic DNA was extracted from each and analyzed by the direct sequencing method. As a result of RAS/RAF gene analysis in 13 target patients, RAS (KRAS) mutation type was found in 5 patients (38.5%).
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究成果から、大腸がんに対する化学療法 FOLFOXは、RAS遺伝子野生型の患者であってもセツキシマブの有効性が示せない症例に対してFOLFOX にベバシズマブを導入した方が適していた可能性がある。大腸癌に対するRAS/RAF遺伝子多型解析を行うことは、末梢神経毒性などの副作用予防もしくは軽減し、かつ有効性を高めるためにも重要である。
|
